Pacira Pharmaceuticals (NASDAQ:PCRX)

CAPS Rating: 1 out of 5

Results 1 - 10 of 10

Recs

0
Member Avatar yoder9339 (< 20) Submitted: 9/7/2014 6:49:22 PM : Outperform Start Price: $102.36 PCRX Score: +3.06

Their product Exparel will continue to gain market share as inpatient surgeries transition to outpatient. This product is gaining traction in the joint replacement procedures. It is a game changer for physicians, patients and surgery centers.

Recs

0
Member Avatar kjfarris (< 20) Submitted: 9/1/2014 3:34:56 PM : Outperform Start Price: $109.27 PCRX Score: -3.17

Produces one drug that is in early adopter phase and starting into more common use. This sky is the limit as more users and uses come on board. Fatal flaw could be if clinical finding of a problem with their one drug occurs; company could die quickly. I would expect this company to be purchased in next two years by a larger pharmaceutical company.

Recs

0
Member Avatar cowcamp (59.03) Submitted: 7/31/2014 7:03:00 PM : Outperform Start Price: $91.92 PCRX Score: +10.14

Excellent reception of current drug program with many in the pipeline.

Recs

0
Member Avatar Ssteffey (< 20) Submitted: 3/28/2014 2:28:54 PM : Outperform Start Price: $62.38 PCRX Score: +58.39

exparel is a game changing product

Recs

0
Member Avatar KKR (< 20) Submitted: 1/28/2014 3:39:38 PM : Outperform Start Price: $64.26 PCRX Score: +50.07

good product with expanding indications

Recs

0
Member Avatar jjschult (< 20) Submitted: 10/11/2012 3:07:15 PM : Outperform Start Price: $17.68 PCRX Score: +438.83

Novel delivery mechanism for generic bipuvicaine that enables 72-hour post-surgery pain relief with a single shot, minimizing the need for opioids. Zero competition and huge target market. Potential to double in 18-24 months.

Recs

0
Member Avatar BKoretz (< 20) Submitted: 10/4/2012 9:55:27 AM : Outperform Start Price: $18.80 PCRX Score: +406.51

Their single product, an injectable, long lasting pain reliever, is going to revolutionize post surgical patient care.

Recs

0
Member Avatar DSmod (35.59) Submitted: 7/3/2012 12:30:39 PM : Underperform Start Price: $16.01 PCRX Score: -492.01

Driven up too high on excitement over one drug--which itself will not bring these guys into profitability.

Recs

0
Member Avatar jsrichards (96.96) Submitted: 6/11/2012 2:55:26 PM : Outperform Start Price: $13.06 PCRX Score: +630.09

This drug will enable providers to send their patients home with minimal narcotics, providing days of minimal post-operative pain, without the untoward complications.

Recs

0
Member Avatar PharmaD (93.71) Submitted: 10/26/2011 11:17:21 PM : Outperform Start Price: $11.39 PCRX Score: +738.40

Nda approval for exparel

Results 1 - 10 of 10

Featured Broker Partners


Advertisement